HC Wainwright Reiterates Buy Rating for Aura Biosciences (NASDAQ:AURA)

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $22.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 210.73% from the company’s current price.

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Trading Up 1.1 %

AURA stock opened at $7.08 on Monday. The company’s 50 day moving average is $7.64 and its 200 day moving average is $8.66. The stock has a market cap of $353.65 million, a price-to-earnings ratio of -4.09 and a beta of 0.30. Aura Biosciences has a 1-year low of $6.33 and a 1-year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). As a group, sell-side analysts forecast that Aura Biosciences will post -1.66 EPS for the current fiscal year.

Insider Buying and Selling

In other Aura Biosciences news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at approximately $2,336,987.64. The trade was a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 23,045 shares of company stock valued at $177,242 over the last quarter. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its position in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after buying an additional 3,612 shares during the period. Geode Capital Management LLC lifted its position in Aura Biosciences by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock valued at $8,327,000 after acquiring an additional 3,972 shares during the period. Wells Fargo & Company MN boosted its stake in Aura Biosciences by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after acquiring an additional 5,930 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Aura Biosciences in the fourth quarter worth about $50,000. Finally, Bank of America Corp DE grew its holdings in Aura Biosciences by 20.5% in the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock worth $422,000 after purchasing an additional 8,709 shares during the period. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.